BrainStorm CEO to Present at the 9th Annual Biotech Showcase

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 5, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 9(th) Annual Biotech Showcase, being held on January 9-11, 2017 at the Hilton San Francisco Union Square in San Francisco, California. Mr. Lebovits will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

http://photos.prnewswire.com/prnvar/20141006/150511

9(th) Annual Biotech Showcase Presentation Details

Date: Monday, January 9
Time: 11:30am Pacific Time
Location: Hilton San Francisco Union Square

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: [phone]
[e-mail]

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: [phone]
[e-mail]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-the-9th-annual-biotech-showcase-300386230.html

SOURCE BrainStorm Cell Therapeutics Inc.